Creating immune-resistant cell therapies for various diseases
Official title: Development of immune evasive strategies for allogeneic cell replacement therapies
Funded at Aleutian Therapeutics LLC · NIH-11184635 · Data updated 2026-11-12
This study is exploring a new way to use donor cells to treat conditions like cancer and Type 1 diabetes, aiming to make these treatments easier and safer for patients by preventing their immune systems from rejecting the cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aleutian Therapeutics LLC NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | May 21, 2025 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $307,091 |
| NIH project number | 1R41AI191979-01 |
| Project ID | NIH-11184635 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with conditions like cancer, Type 1 diabetes, or other diseases that may benefit from cell therapy.
✕Less likely to help
Patients who are not candidates for cell therapy or those with conditions that do not involve immune rejection may not benefit from this research.
What this research studies
This research focuses on developing allogeneic cell therapies, which use donor cells instead of a patient's own cells, to treat diseases like cancer and Type 1 diabetes. The approach involves gene editing pluripotent stem cells to prevent the immune system from rejecting these transplanted cells, eliminating the need for lifelong immunosuppressive drugs. By addressing the challenges of current autologous cell transplants, this research aims to make these therapies more accessible and cost-effective for patients. The project is a collaboration between Aleutian Therapeutics and academic partners, building on promising animal studies.
Why it matters
Potential benefit: If successful, this research could provide patients with safer and more accessible cell therapies without the complications of immunosuppressive medications.
How similar studies have gone: Previous animal studies have shown success with similar gene editing approaches, indicating potential for this novel strategy in human applications.
Where this research is happening
-
Aleutian Therapeutics LLC
Los Angeles, United States Active
Researchers
- Principal investigator: Shen, Christopher — Aleutian Therapeutics LLC
- Study coordinator: Shen, Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.